Funding AI, VR And AR Startups In Medtech For Growth

London aerial view panorama blended with sunset and night with urban architectures. Biotech and Money World Congress 2018Our partner and co-founder, James Shaw, recently participated in a panel discussion about funding artificial intelligence (AI), virtual reality (VR) and augmented reality (AR) start-ups in healthcare at Biotech and Money/Medtech and Money World Congress on 5 February 2018.

Panellists included Isabel van de Keere, CEO at Immersive Rehab, Tommi Lehtonen, CEO at Blueprint Genetics, and Andrew Chapman, Digital Health, Sector Lead at Digital Catapult.

As part of that panel, James wrote an opinion piece for Biotech and Money called The New Cambrian Era for Biotech Startups. Here is the article in full.

________________________________________________________________________

Healthcare is the hottest new sector for start-ups when it comes to new technology like virtual reality (VR), augmented reality (AR), and artificial intelligence (AI). From genetic research and emergency room management to clinical trials, virtual nurses and drug discovery, these new technologies are already creating new applications in healthcare.

According to Deloitte’s 2017 Global Healthcare Sector Outlook, the next top ten technology innovations are expected to bring more value for less in healthcare. These include generation sequencing, 3D-printed devices, immunotherapy, AI, point-of-care diagnostics, VR, social media, biosensors and trackers, convenient care, and telehealth.

Applications of these technologies are already in practice today. In 2016, Shafi Ahmed, a cancer surgeon, operated using a VR camera at the Royal London hospital. A team at Cedars-Sinai hospital in Los Angeles brought VR worlds to patients with chronic pain and allowed the patients to leave the hospital walls and experience a different reality, swim with dolphins, take a walk in the countryside. The teams say the hospital experience can be improved with medical VR, and also lower the cost of care.

Heavyweights like Google, through Google DeepMind Health, are using AI to mine medical records and processing hundreds of thousands of medical data in minutes at Moorfields Eye Hospital and University College London Hospitals (UCLH) Trust. And start-up CareSkore uses AI and a proprietary algorithm based on a combination of clinical, labs, demographic and behavioural data, to determine how likely it is that a patient will be readmitted to a hospital.

These technologies are expected to redesign how healthcare is done and how consumers access and use it. The funding and market value proves that out. According to a 2017 research report from Arcluster, the worldwide healthcare market in AI is expected to surpass $5.5 billion by 2022, just four years from now. However, global prosperity in biotech is not equal.

In 2017, according to PwC/CB Insights’ Healthcare MoneyTree Report, in Q3 2017 there were 184 healthcare deals worth $3.3 billion in the US. Early and expansion stages led to the highest market share of deals in Q3 2017, while seed stage deals increased to 18%, which reversed the trend of the previous three quarters. And according to Pitchbook, funding in biotech topped $9.3 billion across 474 deals in 2017.

But in Europe, the numbers looked different, with the total number of healthcare deals coming in at 50 and worth approximately $1.5 billion during Q3 2017, which experts say represented an eight-quarter low.

It was, however, the third consecutive quarter of decline in deals in Europe. This was countered by an increase in funding due to Softbank’s $1.1 billion investment in Roivant Sciences. The report notes that without the investment into Roivant Sciences, Europe would have seen a third consecutive quarter of decline in funding.

At the same time, in December 2017, the UK government announced the Life Sciences Sector Deal, which includes investment from government and industry.

The idea of creating the perfect blend of start-ups, public and private partnerships, government, and the venture community, which can come together to build out the ecosystem and move the healthcare industry from analogue to digital through new technology, is a priority. But the industry will also face both legal and ethical challenges as it develops.

In February 2017, the European Commission was told to lead the way on developing EU-wide liability rules and ethical standards to deal with artificial intelligence and robotics. The Commission issued a response which emphasised the need for legal certainty and the legal challenges it will face when identifying where liability should fall amongst the different market players.

As the healthcare industry continues to grow with mergers and acquisitions and create entirely new applications for consumers, doctors, and medical personnel, it will need a reliable baseline of liability rules, data protection, and ethical standards to ensure sustainable long-term growth.

 

A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. more information

INFORMATION ABOUT OUR USE OF COOKIES Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience and also allows us to improve our website. By continuing to browse the website, you are agreeing to our use of cookies. A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. We use the following cookies: • Strictly necessary cookies. These are cookies that are required for the operation of our website. They include, for example, cookies that enable you to return to a previous page. • Analytical/performance cookies. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily. The analytical/performance cookies are provided on our behalf by Google Inc. to aid with reporting of user behaviour, market research and improving website functionality. This user behaviour is analysed in order to improve this website. To see how this applies to Google Analytics, visit http://www.google.co.uk/intl/en/analytics/privacyoverview.html. You can stop tracking by Google Analytics by visiting https://tools.google.com/dlpage/gaoptout?hl=en-GB. COOKIE DURATION The strictly necessary session cookies are a temporary cookie which remains in the cookie file of your browser until you close the browser. The other cookies will remain in the cookie file of your browser after the closing of the browser, and will become active again when you reopen this website. The different cookies have different expiration dates. Following expiry of a cookie, a new version of that cookie will be downloaded when you next visit this website, unless you have withdrawn your consent in the meantime. You can block cookies by activating the setting on your browser that allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or parts of our website. Contact If you have any queries regarding this cookie policy please contact us at info@jagshawbaker.com.

Close